Real-world efficacy of DA-EPOCH-R/HD-MTX regimen in CD5-positive diffuse large B cell lymphoma: a single-institute analysis

CD5-positive diffuse large B cell lymphoma (CD5+ DLBCL) is a high-risk lymphoma type. Recently, the PEARL5 (a Phase II trial of DA-EPOCH and Rituximab with HD-MTX therapy for newly diagnosed DLBCL with CD5 expression) study demonstrated the efficacy of the DA-EPOCH-R (cyclophosphamide, etoposide, do...

Descripción completa

Detalles Bibliográficos
Autores principales: Toyama, Kohtaro, Nakayama, Keita, Terasaki, Sachie, Matsumura, Ikuko, Kanaya, Shuhei, Iino, Hiromasa, Noguchi, Hiroyuki, Tahara, Kenichi, Yoshida, Takatomo, Saito, Akio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JSLRT 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158721/
https://www.ncbi.nlm.nih.gov/pubmed/36990773
http://dx.doi.org/10.3960/jslrt.22035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158721/
https://www.ncbi.nlm.nih.gov/pubmed/36990773
http://dx.doi.org/10.3960/jslrt.22035

Ejemplares similares